Consonance Capital Management as of Sept. 30, 2018
Portfolio Holdings for Consonance Capital Management
Consonance Capital Management holds 29 positions in its portfolio as reported in the September 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Pacira Pharmaceuticals (PCRX) | 9.7 | $180M | 3.7M | 49.15 | |
| Retrophin | 6.0 | $113M | 3.9M | 28.73 | |
| United Therapeutics Corporation (UTHR) | 5.9 | $110M | 862k | 127.88 | |
| Puma Biotechnology (PBYI) | 5.7 | $106M | 2.3M | 45.85 | |
| Vanda Pharmaceuticals (VNDA) | 5.5 | $102M | 4.4M | 22.95 | |
| Spectrum Pharmaceuticals | 5.3 | $98M | 5.8M | 16.80 | |
| Nevro (NVRO) | 4.4 | $82M | 1.4M | 57.00 | |
| Karyopharm Therapeutics (KPTI) | 4.4 | $82M | 4.8M | 17.03 | |
| Amarin Corporation (AMRN) | 4.3 | $81M | 5.0M | 16.27 | |
| NuVasive | 4.2 | $77M | 1.1M | 70.98 | |
| Myriad Genetics (MYGN) | 4.1 | $76M | 1.6M | 46.00 | |
| Pacific Biosciences of California (PACB) | 3.9 | $73M | 14M | 5.41 | |
| Luminex Corporation | 3.9 | $72M | 2.4M | 30.31 | |
| Urogen Pharma (URGN) | 3.9 | $72M | 1.5M | 47.23 | |
| Corcept Therapeutics Incorporated (CORT) | 3.8 | $71M | 5.0M | 14.02 | |
| Exelixis (EXEL) | 3.7 | $69M | 3.9M | 17.72 | |
| Vericel (VCEL) | 3.2 | $59M | 4.2M | 14.15 | |
| D Stemline Therapeutics | 2.5 | $46M | 2.7M | 16.60 | |
| Oxford Immunotec Global | 2.1 | $40M | 2.4M | 16.23 | |
| Uniqure Nv (QURE) | 2.0 | $38M | 1.0M | 36.39 | |
| Verastem | 2.0 | $37M | 5.2M | 7.25 | |
| Savara (SVRA) | 1.9 | $35M | 3.1M | 11.16 | |
| Adma Biologics (ADMA) | 1.5 | $28M | 4.5M | 6.21 | |
| Ra Pharmaceuticals | 1.4 | $26M | 1.5M | 18.09 | |
| Theravance Biopharma (TBPH) | 1.3 | $24M | 732k | 32.67 | |
| Catalyst Pharmaceutical Partners (CPRX) | 1.2 | $23M | 6.0M | 3.78 | |
| Sesen Bio | 0.9 | $16M | 7.5M | 2.15 | |
| Innoviva (INVA) | 0.8 | $15M | 1.0M | 15.24 | |
| Biosante Pharmaceuticals (ANIP) | 0.4 | $8.1M | 143k | 56.54 |
